INVO Bioscience, Inc. - רווח לפני ניכוי ריבית, מסים, בלאי ופחת INVO

INVO Bioscience, Inc. (INVO) simplifies the fight against infertility through its INVOcell technology, which allows the embryo to develop within the mother's body. Comparing the company's EBITDA value on GURU.Markets, we see that represents the current level of this metric. However, slow adoption of the system by physicians and a capital deficit create risks. Meanwhile, operations within US clinics provide immunity to geopolitical shocks.

For INVO Bioscience, Inc., the current EBITDA reflects the actual cash flow from core operations, stripped of the impact of depreciation and taxes. Analyzing this metric allows for an assessment of the business transformation's efficiency as it shifts from a narrow profile to a clinic network, revealing true peaks of operational efficiency without accounting distortions, which is critical for minimizing the risks of entering at the peak of the curve.